Mexico City will hold a research protocol to treat 1,666 patients with COVID-19 who will receive treatment with the antiviral remdesivir, the anti-inflammatory baricitinib and the anti-inflammatory cortisone dexamethasone.
These are drugs tested in other countries and their behavior in the Mexican population will now be evaluated, the Secretary of Health, Oliva López Arellano, said in a videoconference.
These drugs, he said, are used in major hospitals in 27 countries in the European Union, the United Kingdom and the United States.
Lee: CDMX and Edomex return to an orange traffic light; these reopens will be allowed
Patients from the “Salvador Zubirán” National Institute of Nutrition, the Citibanamex Temporary Unit, the General Hospital Ajusco Medio, and the General Hospital Enrique Cabrera will participate in this protocol, in collaboration with the Institute of Health for Well-being (Insabi).
This protocol is it is only for patients with less than 10 days of symptomatology evolution and with the need for oxygenation, to avoid reaching the ventilator and more advanced stages, detailed the director of the National Institute of Medical Sciences and Nutrition, David Kershenobich.
The head of government, Claudia Sheinbaum, pointed out that these drugs cannot be in general use, should only be applied by prescription and are exclusives for hospital use under a very specific protocol.
The study will begin on February 18.
In January, the Secretariat of Health of Mexico City, together with a group of experts, identified that ivermectin and azithromycin have had positive effects to stop the replication of the SARS-CoV-2 virus, so these drugs are prescribed to outpatients with COVID.
According to, dependence on ivermectin – recommended mainly for the treatment of mild and moderate pneumonia – has contributed to lower viral load in outpatients and hospitals, with very few negative effects.
However, specialists and Health experts in Mexico ask not to use ivermectin and azithromycin as a treatment against COVID-19, a position that contradicts the Secretariat of Health of Mexico City, which highlighted their positive effects.
Members of the Multidisciplinary Panel of Experts (PME) of the Coordinating Commission of National Institutes of Health and High Specialty Hospitals (CCINSHAE), determined that “there is not sufficient scientific evidence to recommend the use of ivermectin alone, azithromycin alone and ivermectin combined with azithromycin, as a treatment for COVID-19 in none of its stages ”.